CoLabs Int’l, Corp. (CLLB)
| Market Cap | 152.53M |
| Revenue (ttm) | 157,000 |
| Net Income (ttm) | -6.56M |
| Shares Out | 33.90M |
| EPS (ttm) | -0.19 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About CLLB
CoLabs Int’l is an over-the-counter pharmaceutical company with multi-market applications for our revolutionary targeted drug delivery system which is identified as QuantaSphere® Technology. We currently hold 29 issued patents and have an additional 15 patent applications pending. Our technology places OTC drugs, pharmaceuticals, and chemicals into micro-sized, electrostatically charged encapsulates as well as into other types of micro-encapsulates. These encapsulates are then suspended in uniquely designed formulations. This formulation of a h... [Read more]
Financial Performance
Financial StatementsNews
CoLabs Int'l Readies Plan For $6 Million U.S. IPO
CoLabs Int'l, Corp. has filed proposed terms for a $6 million U.S. IPO. The firm is developing topical skin care technologies in the U.S.
CoLabs Int’l IPO Registration Document (S-1)
CoLabs Int’l has filed to go public with an IPO on the NASDAQ.